Symbols / OCGN
OCGN Chart
About
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 471.34M |
| Enterprise Value | 440.77M | Income | -64.02M | Sales | 5.37M |
| Book/sh | 0.01 | Cash/sh | 0.10 | Dividend Yield | — |
| Payout | 0.00% | Employees | 95 | IPO | — |
| P/E | — | Forward P/E | -6.06 | PEG | — |
| P/S | 87.77 | P/B | 130.91 | P/C | — |
| EV/EBITDA | -7.67 | EV/Sales | 82.08 | Quick Ratio | 1.60 |
| Current Ratio | 1.85 | Debt/Eq | 933.03 | LT Debt/Eq | — |
| EPS (ttm) | -0.22 | EPS next Y | -0.24 | EPS Growth | — |
| Revenue Growth | 54.20% | Earnings | 2026-03-05 | ROA | -63.67% |
| ROE | -289.93% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -10.81% | Profit Margin | 0.00% | Shs Outstand | 327.32M |
| Shs Float | 307.88M | Short Float | 14.66% | Short Ratio | 7.72 |
| Short Interest | — | 52W High | 1.96 | 52W Low | 0.52 |
| Beta | 2.81 | Avg Volume | 4.44M | Volume | 1.89M |
| Target Price | $9.00 | Recom | None | Prev Close | $1.41 |
| Price | $1.44 | Change | 2.13% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.00
Mean price target
2. Current target
$1.44
Latest analyst target
3. DCF / Fair value
$-1.49
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.44
Low
$7.00
High
$15.00
Mean
$9.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-20 | main | Chardan Capital | Buy → Buy | $7 |
| 2025-09-19 | main | Chardan Capital | Buy → Buy | $7 |
| 2025-08-04 | main | Chardan Capital | Buy → Buy | $7 |
| 2025-06-24 | main | Chardan Capital | Buy → Buy | $7 |
| 2025-06-24 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-05-12 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-05-12 | main | Chardan Capital | Buy → Buy | $7 |
| 2025-03-06 | main | Chardan Capital | Buy → Buy | $7 |
| 2025-03-06 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-02-13 | main | Chardan Capital | Buy → Buy | $6 |
| 2025-02-13 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-01-23 | main | Chardan Capital | Buy → Buy | $6 |
| 2025-01-13 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-18 | main | Chardan Capital | Buy → Buy | $6 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-11 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-09 | main | Chardan Capital | Buy → Buy | $6 |
| 2024-10-23 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-10-15 | init | Maxim Group | — → Buy | $4 |
| 2024-05-15 | main | Chardan Capital | Buy → Buy | $5 |
- Cell and gene therapy exec Rita Johnson-Greene joins Ocugen as CFO - Stock Titan Mon, 09 Feb 2026 12
- Why The Narrative Around Ocugen (OCGN) Is Shifting After New Fair Value Updates - Yahoo Finance ue, 13 Jan 2026 08
- Ocugen Provides Business Update with Third Quarter 2025 Financial Results - Ocugen, Inc. Wed, 05 Nov 2025 08
- Ocugen (NASDAQ:OCGN) Shares Down 7.4% - Should You Sell? - MarketBeat Sat, 11 Oct 2025 07
- Ocugen (OCGN) Price Target Increased by 26.15% to 8.36 - Nasdaq Wed, 29 Oct 2025 07
- Ocugen: A Retinal Disease Juggernaut In The Making (NASDAQ:OCGN) - Seeking Alpha ue, 23 Sep 2025 07
- OCGN Stock Rises Pre-Market After Gene Therapy Data Shows Promise In Rare Eye Disorder - Stocktwits Mon, 12 Jan 2026 12
- Biotech Ocugen nets $20.85M, cash runway into Q4 2026 - Stock Titan Fri, 23 Jan 2026 08
- Ocugen (OCGN) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance Wed, 05 Nov 2025 08
- Ocugen (NASDAQ:OCGN) Shares Up 1.5% - What's Next? - MarketBeat ue, 16 Dec 2025 08
- Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants - Ocugen, Inc. ue, 12 Aug 2025 07
- Biotech Ocugen prices $22.5M sale of 15M new shares at $1.50 - Stock Titan Wed, 21 Jan 2026 08
- Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock - Yahoo Finance Wed, 21 Jan 2026 08
- Ocugen (NASDAQ: OCGN) CEO to Present on Three BLAs in Three Years at NobleCon21 - Stock Titan hu, 20 Nov 2025 08
- How The Narrative Around Ocugen (OCGN) Is Shifting After The Latest Price Target Change - Yahoo Finance ue, 27 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 207300 | — | — | Stock Award(Grant) at price 0.00 per share. | RAMACHANDRAN RAMESH | Officer | — | 2026-01-02 00:00:00 | D |
| 1 | 3123201 | — | — | Stock Award(Grant) at price 0.00 per share. | MUSUNURI SHANKAR PH.D | Chief Executive Officer | — | 2026-01-02 00:00:00 | D |
| 2 | 10000 | 9095 | — | Purchase at price 0.91 per share. | FERNANDES PRABHAVATHI | Director | — | 2024-11-26 00:00:00 | D |
| 3 | 25000 | 22848 | — | Purchase at price 0.91 per share. | CASTILLO KIRSTEN M | Director | — | 2024-11-22 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -52.79M | -64.83M | -88.59M | -57.80M |
| TotalUnusualItems | 0.00 | |||
| TotalUnusualItemsExcludingGoodwill | 0.00 | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -54.05M | -63.08M | -86.80M | -58.37M |
| ReconciledDepreciation | 1.97M | 704.00K | 480.00K | 229.00K |
| EBITDA | -52.79M | -64.83M | -88.59M | -57.80M |
| EBIT | -54.76M | -65.53M | -89.07M | -58.03M |
| NetInterestIncome | -79.00K | |||
| InterestExpense | 79.00K | |||
| NormalizedIncome | -54.05M | -63.08M | -86.80M | -58.37M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -54.05M | -63.08M | -86.80M | -58.37M |
| TotalExpenses | 58.81M | 71.57M | 91.56M | 58.03M |
| TotalOperatingIncomeAsReported | -54.76M | -65.53M | -89.07M | -58.03M |
| DilutedAverageShares | 271.00M | 244.33M | 214.60M | 195.01M |
| BasicAverageShares | 271.00M | 244.33M | 214.60M | 195.01M |
| DilutedEPS | -0.20 | -0.26 | -0.38 | -0.30 |
| BasicEPS | -0.20 | -0.26 | -0.38 | -0.30 |
| DilutedNIAvailtoComStockholders | -54.05M | -63.08M | -86.80M | -58.37M |
| NetIncomeCommonStockholders | -54.05M | -63.08M | -86.80M | -58.37M |
| NetIncome | -54.05M | -63.08M | -86.80M | -58.37M |
| NetIncomeIncludingNoncontrollingInterests | -54.05M | -63.08M | -86.80M | -58.37M |
| NetIncomeContinuousOperations | -54.05M | -63.08M | -86.80M | -58.37M |
| TaxProvision | 0.00 | -52.00K | ||
| PretaxIncome | -54.05M | -63.08M | -86.80M | -58.42M |
| OtherIncomeExpense | 703.00K | 2.45M | 2.27M | -389.00K |
| OtherNonOperatingIncomeExpenses | 703.00K | 2.45M | 2.27M | -389.00K |
| SpecialIncomeCharges | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | -79.00K | |||
| InterestExpenseNonOperating | 79.00K | |||
| OperatingIncome | -54.76M | -65.53M | -89.07M | -58.03M |
| OperatingExpense | 58.81M | 71.57M | 91.56M | 58.03M |
| ResearchAndDevelopment | 32.13M | 39.57M | 56.16M | 35.11M |
| SellingGeneralAndAdministration | 26.69M | 31.99M | 35.40M | 22.92M |
| GeneralAndAdministrativeExpense | 26.69M | 31.99M | 35.40M | 22.92M |
| OtherGandA | 26.69M | 31.99M | 35.40M | 22.92M |
| TotalRevenue | 4.05M | 6.04M | 2.49M | 0.00 |
| OperatingRevenue | 4.05M | 6.04M | 2.49M | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 121.50K | 121.50K | 121.50K | 121.50K |
| OrdinarySharesNumber | 291.37M | 256.57M | 221.60M | 199.38M |
| ShareIssued | 291.49M | 256.69M | 221.72M | 199.50M |
| TotalDebt | 32.50M | 6.94M | 6.37M | 3.31M |
| TangibleBookValue | 29.63M | 40.56M | 73.98M | 95.82M |
| InvestedCapital | 58.30M | 43.36M | 76.27M | 97.53M |
| WorkingCapital | 40.09M | 25.88M | 69.96M | 95.65M |
| NetTangibleAssets | 29.63M | 40.56M | 73.98M | 95.82M |
| CapitalLeaseObligations | 3.83M | 4.14M | 4.08M | 1.59M |
| CommonStockEquity | 29.63M | 40.56M | 73.98M | 95.82M |
| PreferredStockEquity | 1.00K | 1.00K | 1.00K | |
| TotalCapitalization | 56.98M | 43.36M | 76.27M | 97.53M |
| TotalEquityGrossMinorityInterest | 29.63M | 40.56M | 73.98M | 95.82M |
| StockholdersEquity | 29.63M | 40.56M | 73.98M | 95.82M |
| GainsLossesNotAffectingRetainedEarnings | 48.00K | 20.00K | 26.00K | 0.00 |
| OtherEquityAdjustments | 48.00K | 20.00K | 26.00K | |
| TreasuryStock | 48.00K | 48.00K | 48.00K | 48.00K |
| RetainedEarnings | -340.22M | -286.17M | -223.09M | -131.67M |
| AdditionalPaidInCapital | 366.94M | 324.19M | 294.87M | 225.54M |
| CapitalStock | 2.92M | 2.57M | 2.22M | 2.00M |
| CommonStock | 2.92M | 2.57M | 2.22M | 2.00M |
| PreferredStock | 0.00 | 1.00K | 1.00K | 1.00K |
| TotalLiabilitiesNetMinorityInterest | 52.81M | 23.98M | 34.65M | 9.94M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 31.22M | 6.89M | 6.12M | 2.94M |
| OtherNonCurrentLiabilities | 564.00K | 527.00K | 244.00K | |
| LongTermDebtAndCapitalLeaseObligation | 30.66M | 6.37M | 5.88M | 2.94M |
| LongTermCapitalLeaseObligation | 3.31M | 3.57M | 3.59M | 1.23M |
| LongTermDebt | 27.34M | 2.80M | 2.29M | 1.71M |
| CurrentLiabilities | 21.59M | 17.09M | 28.53M | 7.00M |
| OtherCurrentLiabilities | 2.82M | 151.00K | 357.00K | 293.00K |
| CurrentDeferredLiabilities | 8.37M | 10.53M | 11.22M | |
| CurrentDeferredRevenue | 8.37M | 10.53M | 11.22M | |
| CurrentDebtAndCapitalLeaseObligation | 1.84M | 574.00K | 498.00K | 363.00K |
| CurrentCapitalLeaseObligation | 519.00K | 574.00K | 498.00K | 363.00K |
| CurrentDebt | 1.33M | |||
| OtherCurrentBorrowings | 1.33M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.43M | 1.79M | 2.75M | 1.72M |
| PayablesAndAccruedExpenses | 6.12M | 4.05M | 13.70M | 4.92M |
| CurrentAccruedExpenses | 1.88M | 876.00K | 5.64M | 2.61M |
| Payables | 4.24M | 3.17M | 8.06M | 2.31M |
| AccountsPayable | 4.24M | 3.17M | 8.06M | 2.31M |
| TotalAssets | 82.44M | 64.55M | 108.63M | 105.76M |
| TotalNonCurrentAssets | 20.76M | 21.58M | 10.14M | 3.12M |
| OtherNonCurrentAssets | 4.21M | 4.29M | 4.09M | 1.95M |
| NetPPE | 16.55M | 17.29M | 6.05M | 1.16M |
| AccumulatedDepreciation | -3.16M | -1.23M | -621.00K | -374.00K |
| GrossPPE | 19.71M | 18.52M | 6.67M | 1.54M |
| Leases | 16.09M | 2.09M | 1.60M | 167.00K |
| ConstructionInProgress | 0.00 | 14.54M | 3.05M | 232.00K |
| MachineryFurnitureEquipment | 3.62M | 1.89M | 2.02M | 1.14M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 61.68M | 42.97M | 98.49M | 102.65M |
| OtherCurrentAssets | 3.17M | 3.51M | 7.56M | 7.69M |
| PrepaidAssets | 7.69M | |||
| CashCashEquivalentsAndShortTermInvestments | 58.51M | 39.46M | 90.93M | 94.96M |
| OtherShortTermInvestments | 0.00 | 13.37M | 0.00 | |
| CashAndCashEquivalents | 58.51M | 39.46M | 77.56M | 94.96M |
| CashFinancial | 58.51M | 39.46M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -45.53M | -72.53M | -64.54M | -48.88M |
| RepurchaseOfCapitalStock | 0.00 | |||
| RepaymentOfDebt | 0.00 | -10.00K | ||
| IssuanceOfDebt | 30.00M | 500.00K | 500.00K | 0.00 |
| IssuanceOfCapitalStock | 20.80M | 59.57M | 129.21M | |
| CapitalExpenditure | -3.38M | -10.48M | -4.46M | -939.00K |
| EndCashPosition | 58.82M | 39.46M | 77.56M | 95.11M |
| BeginningCashPosition | 39.46M | 77.56M | 95.11M | 24.19M |
| EffectOfExchangeRateChanges | 28.00K | -5.00K | 25.00K | 0.00 |
| ChangesInCash | 19.33M | -38.10M | -17.57M | 70.92M |
| FinancingCashFlow | 64.86M | 20.88M | 59.48M | 120.68M |
| CashFlowFromContinuingFinancingActivities | 64.86M | 20.88M | 59.48M | 120.68M |
| NetOtherFinancingCharges | -3.70M | -423.00K | -592.00K | -8.53M |
| NetCommonStockIssuance | 38.56M | 20.80M | 59.57M | 129.21M |
| CommonStockPayments | 0.00 | |||
| CommonStockIssuance | 20.80M | 59.57M | 129.21M | |
| NetIssuancePaymentsOfDebt | 30.00M | 500.00K | 500.00K | -10.00K |
| NetLongTermDebtIssuance | 30.00M | 500.00K | 500.00K | -10.00K |
| LongTermDebtPayments | 0.00 | -10.00K | ||
| LongTermDebtIssuance | 30.00M | 500.00K | 500.00K | 0.00 |
| InvestingCashFlow | -3.38M | 3.08M | -16.97M | -1.82M |
| CashFlowFromContinuingInvestingActivities | -3.38M | 3.08M | -16.97M | -1.82M |
| NetOtherInvestingChanges | 761.00K | -877.00K | ||
| NetInvestmentPurchaseAndSale | 0.00 | 13.55M | -13.27M | 0.00 |
| SaleOfInvestment | 0.00 | 17.50M | 0.00 | |
| PurchaseOfInvestment | 0.00 | -3.95M | -13.27M | 0.00 |
| NetPPEPurchaseAndSale | -3.38M | -10.48M | -4.46M | -939.00K |
| PurchaseOfPPE | -3.38M | -10.48M | -4.46M | -939.00K |
| OperatingCashFlow | -42.14M | -62.05M | -60.08M | -47.94M |
| CashFlowFromContinuingOperatingActivities | -42.14M | -62.05M | -60.08M | -47.94M |
| ChangeInWorkingCapital | 3.67M | -13.16M | 9.20M | 2.49M |
| ChangeInOtherCurrentLiabilities | -833.00K | -517.00K | -383.00K | -366.00K |
| ChangeInOtherCurrentAssets | 0.00 | 100.00K | ||
| ChangeInPayablesAndAccruedExpense | 4.14M | -12.34M | 9.49M | 3.50M |
| ChangeInPrepaidAssets | 361.00K | -296.00K | 91.00K | -742.00K |
| OtherNonCashItems | -1.15M | 4.00K | 6.61M | 464.00K |
| StockBasedCompensation | 7.43M | 9.22M | 10.54M | 6.96M |
| AssetImpairmentCharge | 0.00 | 4.07M | 0.00 | 761.00K |
| AmortizationOfSecurities | 0.00 | -182.00K | -99.00K | 0.00 |
| DeferredTax | 0.00 | -52.00K | ||
| DeferredIncomeTax | 0.00 | -52.00K | ||
| DepreciationAmortizationDepletion | 1.97M | 704.00K | 480.00K | 229.00K |
| DepreciationAndAmortization | 1.97M | 704.00K | 480.00K | 229.00K |
| OperatingGainsLosses | 363.00K | -426.00K | ||
| GainLossOnSaleOfPPE | 0.00 | 363.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -54.05M | -63.08M | -86.80M | -58.37M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for OCGN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|